The National Pharmaceutical Pricing Authority (NPPA) has fixed non-ceiling prices of 27 drug formulations manufactured / marketed by companies like Aventis Pharma Ltd, Biological E Ltd, Biotech Medical Private Ltd, Biocon Ltd, Emcure Pharmaceuticals Ltd, Glaxo Smithkline Pharmaceuticls, Lyka Labs Ltd, TTK Healthcare Ltd, Lark Laboratories Ltd, Merck Ltd, Pfizer Ltd and Systopic Laboratories Ltd.
The NPPA has also announced ceiling prices of 63 formulation packs based on bulk drugs Frusemide, Pentoxyfylline, Cefotaxime, Chloroquine Phosphate, Prednisolone, Erythromycin Stearate, Erthyromycin Ethyl Succinate, Erythromycin Base, Oxytetracycline HCL, Ibuprofen combination and vitamins.
The non-ceiling price fixed includes that of Aventis Pharma's imported insuline formulation (Monocomponent Insulin Glargine-100iu/ml).
According to NPPA notification, the ceiling prices fixed on bulk drugs Frusemide (one pack), Pentoxyfylline (one pack), Cefotaxime Sodium (ten packs), Cefotaxime sodium combination (four packs), Carbamezapine (six packs), Chloroquine Phosphate (six packs), Prednisolone (five packs), Erythromycin Stearate (seven Packs), Erthyromycin Ethyl Succinate (six packs), Erythromycin Base (eleven packs), Oxytetracycline HCL (two Packs), Ibuprofen combination (two packs) and Vitamins (two packs) are to be applicable from the second week of November.
The prices have been fixed/ revised in accordance with the provisions of the Drugs (Prices Control) Order (DPCO), 1995 and as per the established criteria and guidelines. Also, while fixing these prices, NPPA has considered the revised norms of Conversion Cost, Packing Charges, Packing Material Cost and Process Loss. The manufacturers are required to work out the pro-rata prices of different pack sizes as the case may be in terms of S.O. No. 83 (E) dated 27.01.98.